文献速递腹部泌尿生殖MR

磁共振肿瘤消退分级预测直肠癌新辅助放化疗后病理完全缓解准确性的系统评价与Meta分析

MR tumor regression grade for pathological complete response in rectal cancer post neoadjuvant chemoradiotherapy: a systematic review and meta-analysis for accuracy.
PubMed 文献 · Eur Radiol · 2020-01-17

该系统评价与Meta分析检索截至2018年8月31日的MEDLINE和EMBASE数据库,纳入6项研究共916例患者,评估磁共振肿瘤消退分级(mrTRG)与病理完全缓解(pCR)及病理T1或更低分期(≤ypT1)的相关性。结果显示mrTRG 1对pCR和≤ypT1特异性高但敏感性欠佳,而mrTRG 1或2敏感性提高但特异性降低。

要点

  • mrTRG 1预测pCR的汇总敏感度32.3%、特异度93.5%,预测≤ypT1的敏感度31.8%、特异度94.7%。
  • mrTRG 1或2预测pCR的汇总敏感度69.9%、特异度62.2%,预测≤ypT1的敏感度71.4%、特异度67.7%。
  • 因mrTRG 1敏感性欠佳,其作为新辅助放化疗后选择低侵袭性治疗的标准可能受限。

核心结论

  • mrTRG 1对pCR和≤ypT1显示高特异性但敏感性欠佳;mrTRG 1或2对pCR和≤ypT1敏感性更高但特异性更低。
  • 由于mrTRG 1敏感性欠佳,其作为新辅助放化疗后低侵袭性治疗标准可能受限。

研究设计与样本

  • 系统评价与Meta分析,遵循PRISMA指南,检索MEDLINE和EMBASE截至2018年8月31日,纳入6项原始研究共916例患者。
  • 纳入研究探讨mrTRG与病理肿瘤消退分级及病理T分期的相关性,采用双变量随机效应模型计算汇总敏感度和特异度。

诊断标准与关键数值

  • mrTRG 1预测pCR的汇总敏感度32.3%(95%CI 18.2-50.6%)、特异度93.5%(95%CI 91.5-95.1%)。
  • mrTRG 1预测≤ypT1的汇总敏感度31.8%(95%CI 16.2-53.0%)、特异度94.7%(95%CI 91.9-96.5%)。
  • mrTRG 1或2预测pCR的汇总敏感度69.9%(95%CI 60.2-78.1%)、特异度62.2%(95%CI 56.2-67.8%)。
  • mrTRG 1或2预测≤ypT1的汇总敏感度71.4%(95%CI 61.6-79.6%)、特异度67.7%(95%CI 59.8-74.7%)。

临床应用与阅片要点

  • mrTRG 1对pCR和≤ypT1特异性高,但敏感性欠佳;mrTRG 1或2敏感性更高但特异性更低。
  • 作者认为,由于mrTRG 1敏感性欠佳,其作为新辅助放化疗后低侵袭性治疗的标准可能受限。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To determine the diagnostic accuracy of magnetic resonance tumor regression grade (mrTRG) for pathological complete response (pCR) and its correlation with pathological findings.

METHODS: Original studies that investigated the correlation of mrTRG with pathological tumor regression grade and pathological T stage were identified in MEDLINE and EMBASE up until August 31, 2018, according to PRISMA guidelines. The search terms included colorectal cancer, chemoradiation therapy, magnetic resonance imaging, and response or regression. Meta-analytic summary sensitivity and specificity for pathologic complete response (pCR) and pathologic T1 or lower than T1 stage (≤ypT1) were calculated using a bivariate random-effects model. The sensitivity and specificity were calculated in both mrTRG 1 and mrTRG 1 or 2, respectively.

RESULTS: Six studies with 916 patients were included. The meta-analytic summary sensitivity and specificity of mrTRG 1 for pCR were 32.3% (95% CI, 18.2-50.6%) and 93.5% (95% CI, 91.5-95.1%), while for ≤ypT1 they were 31.8% (95% CI, 16.2-53.0%) and 94.7% (95% CI, 91.9-96.5%). On the contrary, sensitivity and specificity of mrTRG 1 or 2 for pCR were 69.9% (95% CI, 60.2-78.1%) and 62.2% (95% CI, 56.2-67.8%), while those for ≤ypT1 were 71.4% (95% CI, 61.6-79.6%) and 67.7% (95% CI, 59.8-74.7%).

CONCLUSIONS: mrTRG 1 showed high specificity for pCR and ≤ypT1, but suboptimal sensitivity. mrTRG 1 or 2 showed higher sensitivity for pCR and ≤ypT1, but lower specificity. Because of the suboptimal sensitivity of mrTRG 1, it might be limited as a criterion for less aggressive treatment after neoadjuvant chemoradiotherapy.

KEY POINTS: • Magnetic resonance tumor regression grade 1 shows high specificity for pCR and ≤ypT1, but suboptimal sensitivity. • Magnetic resonance tumor regression grade 1 or 2 shows higher sensitivity for pCR and ≤ypT1, but lower specificity than magnetic resonance tumor regression grade 1 alone.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Jang JK, Choi SH, Park SH, et al. MR tumor regression grade for pathological complete response in rectal cancer post neoadjuvant chemoradiotherapy: a systematic review and meta-analysis for accuracy. Eur Radiol. 2020. PMID: 31953656. doi:10.1007/s00330-019-06565-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。